OliX Pharmaceuticals, Inc (KOSDAQ:226950)
South Korea · Delayed Price · Currency is KRW 115,200
-9,100 (-7.32%)
Jun 12, 2026, 3:30 PM KST
OliX Pharmaceuticals Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -12,248 | -15,743 | -40,659 | -19,102 | -19,495 | -29,715 |
Depreciation & Amortization | 2,376 | 2,454 | 2,626 | 2,642 | 2,075 | 1,630 |
Loss (Gain) From Sale of Assets | -290.33 | -256.32 | -1,649 | 87.48 | -10,506 | - |
Loss (Gain) From Sale of Investments | 52.54 | 76.72 | -349.21 | -439.01 | 35.02 | -11.87 |
Loss (Gain) on Equity Investments | - | - | 8,223 | 900.91 | - | - |
Stock-Based Compensation | 4,067 | 2,777 | 1,163 | 1,226 | 1,594 | 1,932 |
Other Operating Activities | -19,020 | -14,919 | 4,396 | 668.74 | 4,066 | 4,750 |
Change in Accounts Receivable | -138.12 | -5,265 | 3,558 | -3,567 | -73.03 | - |
Change in Inventory | 124.48 | 157.55 | -85.85 | 188.76 | -283.04 | -69.96 |
Change in Other Net Operating Assets | 4,136 | 14,818 | -5,268 | -3,774 | -8,095 | 2,431 |
Operating Cash Flow | -20,940 | -15,900 | -28,045 | -21,168 | -30,683 | -19,054 |
Capital Expenditures | -1,037 | -1,262 | -13,465 | -8,826 | -2,233 | -1,290 |
Sale of Property, Plant & Equipment | 642.22 | 605.4 | 3,248 | 54.34 | 110.04 | 30.6 |
Cash Acquisitions | - | - | - | - | -1,387 | - |
Sale (Purchase) of Intangibles | -629.85 | -595.53 | -170.16 | -239.11 | -301.41 | 164.38 |
Sale (Purchase) of Real Estate | 134.6 | 134.6 | 1,092 | - | - | -24,744 |
Investment in Securities | -96,777 | -104,353 | 10,021 | 43,152 | -51,115 | 41,373 |
Other Investing Activities | 528.11 | 528.11 | 247.85 | 224.94 | -56.54 | -129.21 |
Investing Cash Flow | -97,139 | -104,942 | 973.56 | 34,366 | -54,764 | 15,473 |
Short-Term Debt Issued | - | 1,320 | - | - | - | - |
Long-Term Debt Issued | - | 10,123 | 19,700 | 23,600 | - | 20,000 |
Total Debt Issued | 10,123 | 11,443 | 19,700 | 23,600 | - | 20,000 |
Short-Term Debt Repaid | - | -676 | - | - | - | - |
Long-Term Debt Repaid | - | -8,902 | -1,143 | -30,057 | -786.04 | -382.65 |
Total Debt Repaid | -10,065 | -9,578 | -1,143 | -30,057 | -786.04 | -382.65 |
Net Debt Issued (Repaid) | 58.26 | 1,866 | 18,557 | -6,457 | -786.04 | 19,617 |
Issuance of Common Stock | 6,674 | 7,511 | - | 474.65 | - | 706.28 |
Other Financing Activities | -537.55 | -539.23 | -15.29 | -127.81 | -166.04 | 1,732 |
Financing Cash Flow | 121,196 | 123,839 | 18,541 | -6,110 | 56,048 | 26,555 |
Foreign Exchange Rate Adjustments | -357.27 | -521.87 | 430.69 | -35.09 | -7.87 | 32.94 |
Net Cash Flow | 2,760 | 2,475 | -8,099 | 7,052 | -29,406 | 23,008 |
Free Cash Flow | -21,977 | -17,161 | -41,510 | -29,995 | -32,916 | -20,344 |
Free Cash Flow Margin | -127.31% | -117.01% | -731.17% | -175.77% | -353.16% | -553.66% |
Free Cash Flow Per Share | -1069.92 | -872.60 | -2464.51 | -2078.73 | -2402.08 | -1486.45 |
Cash Interest Paid | 1,177 | 1,229 | 544.13 | 1,225 | 785.3 | - |
Cash Income Tax Paid | 633.32 | 1,665 | -224.03 | 1,516 | 311.2 | 755.25 |
Levered Free Cash Flow | -33,215 | -17,224 | -22,189 | -35,664 | -19,635 | 3,426 |
Unlevered Free Cash Flow | -32,455 | -16,087 | -19,275 | -33,482 | -17,803 | 4,945 |
Change in Working Capital | 4,123 | 9,711 | -1,796 | -7,153 | -8,451 | 2,361 |